<DOC>
	<DOCNO>NCT00979758</DOCNO>
	<brief_summary>The benefit current stem cell transplantation therapy myocardial infarction limit low survival rate stem cell . The purpose study test whether intensive Atorvastatin therapy improve outcome patient impaired leave ventricle function myocardial infarction underwent intracoronary transfer autologous bone marrow cell .</brief_summary>
	<brief_title>Strengthening Transplantation Effects Bone Marrow Mononuclear Cells With Atorvastatin Myocardial Infarction</brief_title>
	<detailed_description>The major challenge successful stem cell therapy myocardial infarction low survival rate implant cell damage tissue . Atorvastatin , HMG-CoA reductase inhibitor , multiple biological activity independent cholesterol-lowering action.This study perform find information strategy Atorvastatin therapy improve survival implant cell . autologous bone marrow stem cell transplantation . Patients 30 80 year age receive autologous bone marrow stem cell transplant Fuwai cardiovascular hospital may eligible study . These patient receive autologous bone marrow cell transplantation intracoronary undergo Percutaneous Coronary Intervention regular high dose Atorvastatin treatment . The objective evaluation perform baseline 12 month follow-up . Heart function test may include follow : 1 . Electrocardiogram ( EKG ) evaluate electrical activity heart . Electrodes place chest transmit information heart machine . 2 . Echocardiogram ( Echo ) ultrasound test use sound wave create image heart examine function heart chamber valve . 3 . Gated acquisition scan nuclear medicine test use small amount radioactive chemical inject vein . A special scanner creates image heart examine beat motion muscle . 4 . MRI evaluate function heart chamber beat motion muscle .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Patients coronary disease undergo PCI . 2 . At 2 month since last episode STelevation myocardial infarction . 3 . Left ventricular ejection fraction &gt; =20 % &lt; =45 % base coronary angiography echocardiography . Any one follow exclusion criterion sufficient disqualify patient study . 1 . Patients nonSTelevation myocardial infarction . 2 . Patients normal leave ventricular function . 3 . Patients mechanical complication myocardial infarction . 4 . Patients malignant tumor . 5 . Patients infection disease . 6 . Less 6 month since last episode stroke . 7 . Patients hematological disease ( leukemia , myeloproliferative disease , myelodysplastic syndrome ) . 8 . AST ( GOT ) exceed 100 IU/L ALT ( GPT ) exceed 100 IU/L . 9 . Leukocytes less 4,000/µL exceed 10,000/µL . 10 . Platelets le 100,000/µL . 11 . Hemoglobin le 10 g/dL . 12 . Pregnant nursing patient , may pregnant , plan become pregnant end study period . 13 . Any reason Clinical Supervisors Clinical Researchers may consider case unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>